NeuBase Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
NeuBase Therapeutics has a total shareholder equity of $14.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $21.5M and $7.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$13.85m |
| Equity | US$14.45m |
| Total liabilities | US$7.01m |
| Total assets | US$21.46m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NBSE *'s short term assets ($14.2M) exceed its short term liabilities ($1.9M).
Long Term Liabilities: NBSE *'s short term assets ($14.2M) exceed its long term liabilities ($5.1M).
Debt to Equity History and Analysis
Debt Level: NBSE * is debt free.
Reducing Debt: NBSE * had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NBSE * has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: NBSE * is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.